Article

Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)

2023-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 913715ef-95e7-5462-a3b9-a3f9cebe369d
DOI: 10.1016/j.ygyno.2023.06.508

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)DOI 10.1016/j.ygyno.2023.06.508Read

The role of niraparib for the treatment of ovarian cancer.Semantic proximity Read

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity Read

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaSemantic proximity Read

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity Read

First-line PARP inhibition in ovarian cancer - standard of care for all?Semantic proximity Read

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity Read

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerSemantic proximity Read

Niraparib for the treatment of ovarian cancer.Semantic proximity Read

Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer.Semantic proximity Read

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancerSemantic proximity Read